Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

DEVELOP NORTH PLC Regulatory Filings 2026

Mar 24, 2026

4965_rns_2026-03-24_87f64c3c-4380-474c-9377-28cb5a694b37.html

Regulatory Filings

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 9487X

Develop North PLC

24 March 2026

DEVELOP NORTH PLC

(the "Company" or "DVNO")

Change of Registered Office Address

The Company announces that, with effect from 21 March 2026, its registered office address has changed to The Key, Bath Lane, Newcastle Helix, Newcastle upon Tyne, NE4 5TQ. 

24 March 2026

For further information regarding the Company (Ticker: DVNO) (LEI: 213800EXPWANYN3NEV68) please call:

Develop North PLC

Michelle Percy

Ian McElroy
+44 (0) 191 222 0099
Tier One Capital Limited (Investment Adviser)

Brendan O'Grady
+44 (0) 191 222 0099
Cavendish Capital Markets Limited (Financial Adviser and Corporate Broker)

Robert Peel

Andrew Worne

Oscar Valeur-Adu
+44 (0) 207 220 0500
Apex Fund Administration Services (UK) Limited (Secretary) +44 (0) 1245 398950

Notes to Editors:

Develop North PLC's investment objective is to provide shareholders with a consistent and stable income and the potential for an attractive total return over the medium to long term, through a diversified portfolio of investments predominantly in the North East of England.

The Company has the financial strength, credibility and professionalism expected of a business listed on the London Stock Exchange, while also offering the flexibility, creativity and common sense of an approachable, local business.

Since the Company's IPO in 2017, it has invested almost £90 million of capital into the North of England and Scotland and has helped support an estimate 12,000 jobs with a gross development value of more than £280 million.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

CROFLFSSVSISFIR